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Clozapine is an atypical antipsychotic medication that is used to treat schizophrenia patients who are resistant to other antipsychotic
drugs. The molecular mechanisms mediating the effects of clozapine are not well understood and its use is often associated with severe
side-effects. In this study, we exposed groups of wild-type zebrafish to two doses of clozapine (‘low’ (20 µg/L) and ‘high’ (70 µg/L)) over
a 72-h period, observing dose-dependent effects on behaviour. Using RNA sequencing (RNA-seq) we identified multiple genes
differentially expressed in the zebrafish brain following exposure to clozapine. Network analysis identified co-expression modules
characterised by striking changes in module connectivity in response to clozapine, and these were enriched for regulatory pathways
relevant to the etiology of schizophrenia. Our study highlights the utility of zebrafish as a model for assessing the molecular
consequences of antipsychotic medications and identifies genomic networks potentially involved in schizophrenia.
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INTRODUCTION
Schizophrenia is a severe psychiatric disorder affecting more than
21 million people worldwide and contributing significantly to the
global burden of disease.1,2 It is characterised by symptoms of
social isolation, apathy and lack of drive, interference with thought
processes, hallucinations and delusions.3 There is no cure for
schizophrenia; current treatments act by reversing the symptoms
of disease rather than preventing the development of underlying
pathology. These medications have relatively low efficacy for
treating cognitive impairment and are not an efficient therapeutic
of long term disability given the severe side-effects often
associated with their use.4 Between 5% and 25% of schizophrenia
patients are resistant to the most commonly prescribed anti-
psychotic medications,5 and clozapine is a second-generation
antipsychotic often prescribed to patients with such treatment-
resistant schizophrenia. Although clozapine has been shown to
have increased effectiveness compared to other commonly
prescribed antipsychotic drugs,6,7 over 40% of patients treated
with clozapine show an inadequate response8 and its use is
associated with severe side-effects. For example, patients pre-
scribed clozapine need to be carefully monitored for the
development of serious blood disorders such as agranulocytosis.9
The molecular mechanisms by which clozapine acts to alleviate
the symptoms of schizophrenia are poorly understood.10 Identify-
ing clozapine-related gene expression changes would help in
understanding the mechanisms and side-effects of clozapine, and
potentially identify molecular pathways and gene networks
involved in schizophrenia.
To date, few studies have characterised gene expression
changes in the brain associated with exposure to clozapine.
Duncan and colleagues identified several differentially expressed
genes in the mouse brain following clozapine exposure, including
genes encoding potassium channel subunits.11 Another study
identified clozapine-induced expression changes in the mouse
striatum and cortex, including genes involved in
neurotransmission, calcium homoeostasis and signal transduc-
tion.12 A study in rats identified clozapine-associated changes in
the expression of genes involved in pathways, such as protein
metabolism, nucleotide metabolism and signal transduction.13
Finally, Rizig and colleagues identified changes in the expression
of glutamatergic, GABAergic, serotonergic, retinoid and G-coupled
receptor genes in the mouse brain following clozapine exposure.14
Despite these preliminary findings, transcriptional responses to
clozapine exposure have not been fully characterised.
Zebrafish (Danio rerio) is a widely used vertebrate model in
neuroscience research15; there are multiple advantages of using
zebrafish as a model, including high organizational and physio-
logical similarity with mammalian brain structures,15 considerable
(>70%) genomic orthologuey with human,16 rapid development
and ease of genetic and other experimental manipulations.15
Compared to other models, the use of zebrafish is cost- and space-
efficient, allowing the generation of larger sample sizes compared
to analyses of rodents.15 Zebrafish have been used to model traits
associated with several human psychiatric disorders including
aggression, attention-deficit hyperactivity disorder (ADHD), post-
traumatic stress disorder (PTSD), addiction and schizophrenia.17,18
Similarly, zebrafish models have been useful in tracking beha-
vioural changes in response to epilepsy treatments,19 identifying
activators of a metabolic fasting response20 and determining the
effectiveness of commonly used medication in the treatment of
Parkinsonian-like symptoms.21
In this study, we exposed zebrafish to two doses of clozapine
and assessed behavioural and gene expression changes. We used
RNA sequencing (RNA-seq) and co-expression network analysis to
identify transcriptomic-wide changes in the zebrafish brain and
modules of co-expressed genes sensitive to clozapine exposure.
Our study highlights the utility of zebrafish as a model for
assessing the molecular consequences of antipsychotic medica-
tions and identifies genomic networks potentially involved in
schizophrenia.
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RESULTS
Overview of experimental approach
We exposed groups of wild type zebrafish to two doses of the
antipsychotic drug clozapine (‘‘low’’ (20 µg/L) and ‘high’ (70 µg/L))
over a 72-h period. We assessed individual fish (including during
spawning and feeding) to analyse changes in behaviour
associated with clozapine exposure. Total RNA was isolated from
brain tissue and used for messenger RNA-sequencing (RNA-seq)
for samples exposed to water control (n= 16), dimethyl sulfoxide
(DMSO) vehicle (n= 16), ‘low’’ clozapine exposure (n= 16) and
‘high’ clozapine exposure (n= 16). After stringent quality-control
and pre-processing (see Methods), the RNA-seq data were used
for differential gene expression analysis to identify clozapine-
induced expression changes. Network analysis was performed to
identify modules of co-expressed genes sensitive to clozapine
exposure and gene ontology (GO) analysis was used to identify
pathways and functions enriched in each of the clozapine
exposure-associated modules. Supplementary Table 1 summarises
phenotypic measures and RNA quality data for each of the
individual samples used in this study. A schematic overview of the
study is given in Supplementary Fig. 1 and additional details are
provided in the Methods.
Clozapine exposure had no general effects on fish health
We measured the body weight (g), fork length (cm), liver weight
(mg) and brain weight (mg) and calculated the condition factor
(k), hepatosomatic index (HSI) and brain-body ratio (BBR) for each
individual fish (see Methods and Supplementary Table 1). None of
these metrics differed significantly between groups (P > 0.05)
(Supplementary Table 2), indicating that neither clozapine nor
vehicle (DMSO) is associated with changes in any of these
physiological characteristics under the experimental conditions
tested in this study.
Clozapine exposure induces striking behaviour effects in zebrafish
We did not identify any significant behavioural differences
between the water and DMSO groups at any of the time-points
tested (Supplementary Table 3A). In contrast, we found that
clozapine exposure had a significant dose-dependent effect on
tank position during each of the behavioural phases (‘general
time’ (Fig. 1a), feeding (Fig. 1b) and spawning (Fig. 1c), all
P < 2.78E-03 (Bonferroni corrected P-value for the 18 tests))
(Supplementary Table 3B), with the ‘high’ exposure group
spending a much larger proportion of time at the top of the
tank. Conversely, clozapine exposure was associated with less time
spent at the bottom of the tank during each of the three
assessment periods (all P < 2.78E-03). Changes in the proportion of
time spent in the middle of the tank were less pronounced, with
clozapine exposure having a significant effect during ‘general
time’ and spawning, but not feeding. Representative videos of
clozapine-induced changes in tank position during ‘general time’
can be seen online at https://doi.org/10.6084/m9.figshare.9638900
(DMSO exposure) and https://doi.org/10.6084/m9.figshare.9638903
(‘high’, 70 µg/L exposure). The original videos are also available
online (see Methods). Clozapine exposed fish did not show any
signs of respiratory or other types of stress that might explain the
increased time spent at the top of the tank.
Clozapine exposure is associated with the altered gene expression
High-quality RNA was obtained from all individual fish included in
this study (minimum, mean and maximum RNA integrity numbers
(RIN) were 8.30, 9.37 and 10.00, respectively) (Supplementary
Table 1). Following RNA sequencing and stringent quality control
(QC) of the raw data (see Methods), we obtained an average of
33,089,096 (standard deviation (SD)= 8,636,715) quality-trimmed
pair-ended reads per sample (Supplementary Table 4), with no
difference in read-depth between exposure groups (t-test water vs
DMSO P= 0.96 and ANOVA DMSO, 20 µg/L clozapine and 70 µg/L
clozapine P= 0.25). In total, 20,837 genes were reliably detected
and used for differential expression analysis (see Methods). To
identify clozapine exposure-associated changes we performed a
likelihood ratio test (LRT) using exposure (i.e. DMSO, 20 µg/L
clozapine, and 70 µg/L clozapine), sex (male and female) and
experimental week (first or second) as independent variables.
Quantile-quantile (Q–Q) plots (Supplementary Fig. 2) and volcano
plots (Supplementary Fig. 3A, B) of the association statistics from
these analyses indicate that there are more striking differences
Fig. 1 Clozapine exposure is associated with behaviour changes of zebrafish in the tank. Clozapine exposure induced a significant dose-
dependent increase in the time spent at the top of the tank during a ‘general time’, b feeding and c spawning. All P-values < 2.78E-03
(Bonferroni corrected P-value for the 18 tests). The error bars represent the standard deviation.
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between DMSO and clozapine than between water and DMSO.
Overall results for each detectable gene are provided in the
Supplementary Data file. Although two genes (cremb and
si:ch211-207b24.4) showed expression differences between the
water control and DMSO vehicle groups (FDR < 0.10) (Supplemen-
tary Data), neither of these was associated with exposure to
clozapine. In total, the expression of twelve genes was significantly
(FDR < 0.10) associated with clozapine exposure (Table 1 and
Fig. 2). Both doses of clozapine exposure were associated with a
reduction in the expression of five genes (arrdc3b (P= 5.05E-06),
xpo1a (P= 8.12E-06), odc1 (P= 1.07E-05), slc16a9b (P= 4.25E-05)
and angptl4 (P= 4.59E-05) (Fig. 2)), and an increase in expression
of four genes (ckma (P= 1.11E-06), mylpfa (P= 2.77E-05), slc39a3
(P= 3.54E-05) and tnnt3b (P= 4.46E-05) (Fig. 2)). The remaining
differentially expressed genes were characterised by less consis-
tent changes, with opposite-direction effects associated with ‘low’
and ‘high’ doses of clozapine (xpo1a (P= 8.12E-06), ptgdsb.1
(P= 2.38E-05) and nutf2l (P= 5.36E-05)) (Fig. 2). All but two
(slc39a3 and nutf2l) of these differentially expressed genes have
one (or more) known human orthologues (Table 1), many playing
a role in functional pathways relevant to schizophrenia (see
Discussion). Of note, there was no evidence for any significant
interaction between the gene expression responses to exposure
and sex (Supplementary Figs 3C and 4), indicating that exposure
to clozapine does not have differential effects on gene expression
in males and females.
Co-expression gene modules show dosage sensitive variation in
connectivity following clozapine exposure
We next used weighted gene co-expression network analysis
(WGCNA) to explore system-level changes in zebrafish brain gene
expression following clozapine exposure (see Methods). We
created a network of co-expressed genes using RNA-seq data
from all samples exposed to vehicle (DMSO) (n= 16), ‘low’
clozapine exposure (n= 16) and ‘high’ clozapine (n= 16), in total
identifying 34 discrete co-expression modules (Table 2). Of these
20 were characterised by significant changes in intramodular
connectivity (the sum of connection strengths with the other
module genes, i.e. the extent to which genes within the same
module are connected to each other) in response to clozapine
exposure (Bonferroni corrected P= 1.47E-03, accounting for
the total number of modules tested). Table 2 shows the average
intramodular connectivity within each module for each exposure
group, highlighting the extent to which different modules show
varying patterns of altered connectivity after clozapine exposure.
We investigated whether there was an over-representation of
specific Gene Ontology (GO) categories in each of the clozapine-
associated co-expression modules. Ten of the clozapine-
associated modules had at least one overrepresented GO term
(Bonferroni P < 3.34E-05, corrected for 1497 GO terms present in
all the modules tested) (Supplementary Table 5), with many of the
modules highly enriched for pathways directly related to
schizophrenia and the pharmacology of clozapine. The largest
module (‘Module 1’), which comprises 380 genes, was charac-
terised by a dramatic increase in connectivity associated with
exposure to clozapine (mean connectivity control= 0.59, mean
connectivity ‘low’ clozapine exposure= 3.02, mean connectivity
‘high’ clozapine exposure= 32.43, ANOVA P= 7.67E-216, Fig. 3
and Table 2); in essence this reflects the coordinated upregulation
of a discrete co-expressed set of genes in response to clozapine.
‘Module 1’ is enriched for genes involved in G-protein-coupled
receptor (GPCR) activity (P= 1.56E-6) (Fig. 4 and Supplementary
Table 5); this is interesting given the known interaction between
clozapine and several G-protein-coupled receptors (GPCRs)
including the dopamine D2 receptor.22,23 ‘Module 5’, in contrast,
is characterised by a significant decrease in connectivity after
clozapine exposure (mean connectivity control= 6.09, ‘low’
clozapine exposure= 3.18, ‘high’ clozapine exposure= 3.01,
ANOVA P= 8.08E-14, Fig. 5 and Table 2); this reflects a module
of co-expressed genes that is disrupted following clozapine
exposure, with GO analysis showing it to be enriched for genes
related to cytoplasmic translation (P < 2.93E-98, Supplementary
Fig. 7 and Supplementary Table 5). The connectivity values for the
remaining clozapine-associated modules are shown in Supple-
mentary Fig. 5 with enriched GO categories shown in Supple-
mentary Table 5 and Supplementary Figs 6–13.
DISCUSSION
In this study we examined behavioural and transcriptional
responses to clozapine exposure. First, we found that clozapine
had a significant dose-dependent effect on swimming behaviour,
with elevated exposure associated with a dramatic increase in the
proportion of time spent at the top of the tank. Previous studies
Table 1. Differentially expressed genes significantly associated with exposure to clozapine. Statistics for all detectable genes are given in
Supplementary Table 5.
Gene ID Gene symbol Base mean
read-counts
log2 fold change
(Control vs ‘Low’)
log2 fold change
(Control vs ‘High’)
P-value FDR Human homolog(s)
ENSDARG00000035327 ckma 85.99 2.82 1.06 1.11E-06 0.01 CKM
ENSDARG00000067593 sco1 66.10 −0.76 −0.66 1.22E-06 0.01 SCO1
ENSDARG00000036028 arrdc3b 282.33 −0.60 −0.84 5.05E-06 0.04 ARRDC3
ENSDARG00000078041 xpo1a 303.69 −0.21 −0.37 8.12E-06 0.04 XPO1
ENSDARG00000007377 odc1 220.10 −0.36 −0.42 1.07E-05 0.04 ODC1
ENSDARG00000027088 ptgdsb.1 745.87 −0.79 0.36 2.38E-05 0.08 PTGDS; LCN6; LCN15; LCN9; LCN1;
LCN10; OBP2A; AL355987.1; LCNL1;
LCN8; OBP2B; PAEP
ENSDARG00000053254 mylpfa 63.39 2.29 0.52 2.77E-05 0.08 MYLPF
ENSDARG00000101434 slc39a3 26.23 0.75 0.32 3.54E-05 0.09 −
ENSDARG00000104687 slc16a9b 134.57 −0.39 −0.57 4.25E-05 0.09 SLC16A9
ENSDARG00000068457 tnnt3b 70.05 2.01 0.27 4.46E-05 0.09 TNNT3
ENSDARG00000035859 angptl4 193.64 −0.43 −0.84 4.59E-05 0.09 ANGPTL4
ENSDARG00000014499 nutf2l 29.00 −0.22 0.49 5.36E-05 0.09 −
FDR false discovery rate
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have shown that clozapine induces specific behavioural profiles in
larval zebrafish.24,25 Furthermore, our findings corroborate those
from a recent study that showed that clozapine acts to rescue
aberrant swimming behaviour in zebrafish lacking the dopamine
transporter gene which normally hover near the tank bottom.26
Second, our brain RNA-seq analyses identified altered expression
of several genes in response to clozapine exposure. Several of the
individual genes influenced by clozapine changed additively with
clozapine dose, although for other genes the exposure-associated
changes were more complex with opposite directions of
differential expression in the low and high exposure groups;
although the mechanism underlying these differences are not
known, they are interesting given previous work highlighting
differential effects of low- and high-doses in mice.27 Finally, we
observed striking shifts in the connectivity between co-expressed
genes in modules enriched for functions related to schizophrenia
and the known pharmacology of clozapine. To our knowledge this
represents the most systematic analysis of gene expression
changes in the brain associated with exposure to clozapine,
prioritizing genes and molecular pathways for future studies of
schizophrenia and antipsychotic medications.
Several human orthologues of the individual zebrafish genes
associated with clozapine exposure in this study are noteworthy
for their hypothesised role in schizophrenia and/or the action of
clozapine. For example, CKM (orthologue of ckma, which was
upregulated following clozapine exposure) encodes a creatine
kinase that catalyzes the phosphorylation of creatine in muscle.
The expression of the heterodimer CKMB consisting of one muscle
(CKM) and one brain-type (CKB) subunit has been shown to be a
robust biomarker for acute myocardial infarction,28 an interesting
observation given the elevated risk of myocarditis following
clozapine exposure.29 Of note, elevated levels of serum CKM have
been reported after both clozapine30 and olanzapine treatment.31
CKM is expressed in Purkinje neurons and is thought to be
involved in unique calcium metabolism of these neurons and their
role in cerebellar motor learning.32,33 Also of interest in the
Fig. 2 Clozapine exposure is associated with significant changes in the expression of twelve genes. Boxplots showing the expression levels
of the twelve genes differentially expressed (FDR < 0.10) for the DMSO (grey), ‘low’ dose (20 µg/L clozapine; blue) and ‘high’ dose (70 µg/L
clozapine; red) exposure samples. P-values are presented in each of the boxplots.
J. Viana et al.
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context of clozapine-induced side effects is ANGPTL4 (an
orthologue of angptl4, which was downregulated in response to
clozapine); this gene is associated with triglyceride and high-
density lipoprotein cholesterol levels34 and might be relevant to
the elevated risk of type 2 diabetes in schizophrenia patients
prescribed clozapine.35
Also noteworthy is SCO1 (orthologue to sco1, which was
downregulated following clozapine exposure). This gene encodes
cytochrome C oxidase assembly protein 1, a copper metallochaper-
one that is essential for the maturation of cytochrome c oxidase
subunit II and plays an important role in the regulation of copper
homoeostasis.36 Copper plays a key role in functions such as
mitochondrial activity and myelination37 and is transported from
the bloodstream across the blood–brain barrier into astrocytes
and then neurons via the copper uptake protein 1 (CTR1).38 Inside
the cell, copper is delivered to the trans-Golgi network and from
there distributed to metallochaperones including SCO1, which
transport it to the mitochondria.39 Schizophrenia patients have
been shown to exhibit altered plasma copper levels40 and agents
which decrease copper levels produce schizophrenia-like beha-
vioural in rats.41 One possible hypothesis would be that clozapine
regulates the abnormal levels of copper observed in schizophrenia
by altering the expression of SCO1, however more work is needed
to understand the mechanism of action.
Another interesting human orthologue is ODC1 that encodes
ornithine decarboxylase 1 (orthologue to odc1, which is down-
regulated following clozapine exposure), an enzyme that catalyzes
the conversion of ornithine into putrescine.42 Putrescine is a
polyamine, together with spermine, and spermidine, and plays a
major role in the regulation of cell growth and differentiation,
Table 2. Co-expression gene modules associated with clozapine exposure.
Connectivity
Module Number
of genes
ANOVA P Mean connectivity
(control)
Mean connectivity
(‘low’)
Mean connectivity (high) GO terms over-
represented
1 380 7.67E-216 0.59 3.02 32.43 3
2 324 2.88E-155 2.36 1.12 22.02 0
3 182 0.06 13.72 15.42 12.00 –
4 105 5.41E-08 3.81 1.89 2.81 12
5 99 8.08E-14 6.09 3.18 3.01 17
6 79 4.25E-06 2.63 1.36 1.87 0
7 73 5.28E-32 0.70 1.09 4.16 2
8 69 8.38E-35 1.37 0.60 5.09 7
9 57 4.70E-52 0.60 0.03 7.76 0
10 55 0.14 3.06 4.57 3.60 −
11 49 1.35E-04 2.53 2.35 1.07 10
12 42 3.81E-07 0.60 1.42 1.06 0
13 41 1.01E-04 0.73 1.37 1.89 8
14 41 0.11 1.72 1.33 2.04 −
15 37 0.03 1.40 1.32 0.84 −
16 35 1.87E-14 0.19 1.35 2.26 9
17 33 0.21 1.87 2.24 1.54 −
18 33 5.05E-04 2.64 3.47 1.52 −
19 31 4.55E-10 1.40 0.14 2.45 4
20 31 2.77E-08 0.77 5.00 3.90 0
21 30 1.22E-03 1.56 2.16 3.57 −
22 27 9.34E-17 0.34 0.60 5.32 0
23 26 0.99 3.00 2.87 2.98 −
24 24 0.11 1.65 2.59 3.09 −
25 24 2.61E-04 2.72 3.24 1.13 3
26 24 0.99 3.11 3.02 3.03 −
27 23 0.02 1.51 0.64 1.52 −
28 23 0.23 2.74 3.72 2.29 −
29 23 2.94E-04 0.98 1.91 3.13 0
30 22 7.34E-05 1.47 0.50 2.99 0
31 22 5.67E-05 2.01 1.49 3.96 0
32 22 0.04 1.56 2.76 1.48 −
33 21 2.91E-19 0.10 0.15 4.21 0
34 20 0.48 2.89 2.37 1.95 –
Modules are listed ranked by size. 20 modules (depicted in bold in the table) were characterised by a significant change in intramodular connectivity
associated with clozapine exposure (Bonferroni corrected P-value= 1.47E-03, accounting for the total number of modules tested). Enriched gene ontology
(GO) terms for each module are presented in Supplementary Table 5. Rows in bold depict significant modules associated with clozapine exposure
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metabolic pathways, and cell membrane functions in mammalian
systems.43 It has been suggested that polyamines may be
involved in the pathophysiology of schizophrenia and other
mental health conditions.44 Ornithine, ODC1 and putrescine are
involved in L-arginine metabolism,45 which has also been
implicated in the pathogenesis of schizophrenia.46–49 Although
studies in schizophrenia have found no differences in ODC1 levels
or activity in three different brain regions,50,51 levels of plasma
ornithine have been shown to be elevated in patients.52
Finally, our results also highlight ARRDC3, which encodes
Arrestin Domain Containing 3 (orthologue to arrdc3b, which is
downregulated following clozapine exposure), an adapter
protein that plays a role in regulating cell-surface expression
of adrenergic receptors and other GPCRs.53–56 ARRDC3 has also
been shown to be differentially expressed in the prefrontal
cortex in schizophrenia.57 This is an interesting finding since
GPCRs play a major role in schizophrenia and its treatment.22,23
Further evidence for disrupted GPRC activity comes from our
systems-level analysis, with the largest co-expression module
(‘Module 1’) being highly enriched for genes related to GPRC
activity (Supplementary Table 5) characterised by a dramatic
increase in connectivity following clozapine exposure in a dose-
dependent manner. Altered levels of several G-protein-coupled
receptor kinases (GRKs), which are involved in GPCRs desensi-
tisation, have been found previously after clozapine and
haloperidol treatment.58 GPCRs are phosphorylated by GRKs
and subsequent bind to arrestin, which stops receptor-G-protein
interaction and induces receptor internalisation.56
Several other functional pathways are enriched amongst
modules highlighted by our co-expression network analyses
(Supplementary Table 6). ‘Module 4’ and ‘Module 13’, for example,
are highly enriched for GO categories related to mitochondrial
function, which is interesting given the evidence for a link between
mitochondrial dysfunction and pathogenesis of schizophrenia,59,60
and data showing an effect of clozapine on mitochrondrial
activity.61,62 This is also interesting considering the downregulation
of sco1 following clozapine exposure discussed above. Our data
lend support to the hypothesis that impairments to mitochondrial
activity underlie some of the metabolic side-effects (e.g. insulin
resistance, hepatic steatosis and accelerated weight gain) of
clozapine.61,63 Other functional pathways highlighted by our co-
expression network analyses include several implicated in schizo-
phrenia including axon development (‘Module 7’)64 and circadian
processes (‘Module 11’).65 Overall, more dramatic changes in
response to clozapine were identified at the co-expression network
level highlighting the power of this approach for identifying
changes in discrete gene pathways.
Although comparisons with previous studies of clozapine-
induced gene expression changes in rodents are difficult given
the different models, technologies and experimental strategies
employed, it is interesting that several common pathways appear
to be represented—for example calcium metabolism, signal
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Fig. 3 Example of a module characterised by increased connectivity between co-expressed genes following clozapine exposure. a There
is a highly significant increase in connectivity within ‘Module 1’ following clozapine exposure, with the most dramatic increase seen following
exposure to a ‘high’dose of clozapine. b Connectivity for individual genes in ‘Module 1’ is notably higher following clozapine exposure relative
to connectivity in the DMSO control group. c Visual representation of connectivity between individual genes in ‘Module 1’ following clozapine
exposure (fifty genes with higher connectivity), highlighting the clear dose-response relationship. Thicker lines denote higher connectivity.
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transduction and lipid metabolism which were also highlighted in
a study on rat brain.12 There are, however, several limitations to
this study that should be considered when interpreting our
findings. First, despite the advantages of using zebrafish as a
model for genomics and neuroscience,15 there are important
differences between transcriptional control in zebrafish and
human. Zebrafish are non-mammalian, with a less complex central
nervous system (CNS) than humans, although they show similar
patterns of brain development and conserved brain structure with
mammals.15,66 Furthermore, there is a high degree of genetic
orthologuey to human, with >70% of the genome conserved.16
Second, our analyses were performed on bulk brain tissue
comprising a mix of brain regions and different neural cell-
types. Future work should focus on transcriptionally profiling
discrete populations of cells from specifically dissected brain
regions. Third, we only assessed two acute exposures to clozapine;
although this enabled us to dissect the primary response
pathways following clozapine exposure without adaptive
responses acting as a confounder, our analyses are not
representative of the chronic polypharmaceutical exposures
experienced by patients with schizophrenia. Finally, although
our study represents the most systematic analysis of gene
expression changes associated with clozapine yet undertaken,
we only quantified gene expression in a relatively small number of
individuals from an individual zebrafish strain and our findings
warrant further replication.
In summary, we provide evidence for behavioural and gene
expression changes in the brain—at both the single gene and
systems level—following exposure to clozapine. Our study high-
lights the utility of zebrafish as a model for assessing the
molecular consequences of antipsychotic medications and iden-
tifies genomic networks potentially involved in mediating the
response to clozapine and the etiology of schizophrenia.
METHODS
Fish husbandry
All animal procedures were conducted according to guidelines of the
United Kingdom’s Home Office and approved by The University of Exeter
Animal Ethics Committee. Wild type WIK strain adult zebrafish were
maintained according to the conditions reported in Paull et al.67
(originating from a stock population (October 2014)). The experimental
tanks used were 300mm× 300mm× 600mm and were filled with 15 L of
water. A flat constructed plastic base was placed in the bottom of each
tank and opaque dividers were placed in between adjacent tanks to
prevent visual interactions between fish in neighbouring tanks. Each tank
was divided into three main areas using a grid (bottom, middle and top).
Mains tap water was filtered by reverse osmosis (Environmental Water
Systems (UK) Ltd.) and reconstituted with Analar-grade mineral salts to
Fig. 4 Enrichment of functional pathways related to G-protein-coupled receptor activity in ‘Module 1’, which is characterised by
dramatically elevated gene connectivity following clozapine exposure. The applications ‘EnrichmentMap’ (v3.2.0) and AutoAnnotate’ (v1.3)
in Cytoscape (v3.7.1) were used to generate this figure. GO terms are ordered by enrichment P-value with smaller numbers representing
smaller P-values. GO terms were clustered by ‘gene set description’ (‘EnrichmentMap’). Overrepresented GO terms are circled with a red border
(Bonferroni P < 3.34E-05, see Supplementary Table 6). The width of the edges is proportional to the number of genes in common between
GO terms.
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standardized synthetic freshwater (final concentrations to give a con-
ductivity of 300mS: 122mg/L CaCl22H2O, 9.4 mg/L NaHCO3, 50mg/L
MgSO47H2O, 2.5 mg/L KCl, 50 mg/L Tropic Marin Sea Salt), aerated and
heated to 28 °C in a reservoir, before it was supplied to each aquarium
using a flow-through system. Tanks were aerated and supplied with a flow
rate of 48 L/day of water maintained at 28 ± 0.5 °C and pH 7–7.5. Fish were
maintained under a 12 h light:dark cycle, including dawn and dusk
transition periods of 30min and were fed live Artemia nauplii (ZM Premium
Grade Artemia; ZM Ltd.) once daily day at 11.00 a.m., except on the final
day prior to sampling. Fish were maintained in large mixed-sex holding
tanks prior to the experiment and two males and two females were
randomly allocated into each experimental tank on day 1 of the
experiment (Supplementary Fig. 1 shows a diagram of the experiment).
Exposure of zebrafish to clozapine
Fish were exposed to two different concentrations of clozapine (‘low’
concentration: 20 µg/L and ‘high’ concentration: 70 µg/L) and dimethyl
sulfoxide (DMSO; 70 µl/L) was used as a vehicle to dissolve clozapine.
DMSO and water control were also used in parallel.: 24 h after the
introduction of the fish to the exposure tanks, to allow for acclimation, the
chemical exposure was initiated by adding pre-prepared solutions of
clozapine to each tank to reach the desired concentration (two tanks per
condition), and initiation of a flow through exposure system in which
appropriate concentrations of stock solutions of clozapine, DMSO or water
were pumped into each tank using a peristaltic pump to maintain the
exposure concentrations and water flow during the exposure period. Flow
rates were monitored daily to ensure the chemical concentrations
remained consistent. Fish were fed twice daily, once with live Artemia
nauplii (ZM Premium Grade Artemia; ZM Ltd.) and another time with
TetraMin tropical flake food (Tetra; Melle, Germany), to satiation. Stock
solutions were replaced daily. After 72 h of exposure, all fish were sacrificed
humanely using a lethal dose of benzocaine in accordance with UK Home
Office regulations. The brains were dissected and weighed. All samples
were snap frozen in liquid nitrogen and stored at −80 °C. The experiment
was repeated in two consecutive weeks resulting in four independent
tanks containing two males and two females per treatment. The total
number of fish was 64, 16 per exposure group.
Measures of fish health
During sampling, the wet weight and fork length were recorded, and the
condition factor was calculated (k= [body weight (g) × 100]/[fork length
(cm)]3). The hepatosomatic index (HSI= liver weight (mg)/[total weight
(mg)− liver weight (mg)] × 100) and brain-body ratio (BBR= brain weight
(mg)/[total weight (mg)− liver weight (mg)] × 100) were also calculated.
These measurements can be found in Supplementary Table 1. To identify
differences between the two control groups in each of the metrics (body
weight, body length, k, HSI and BBR) we performed a linear regression in
females and males separately using exposure (water and DMSO) and week
of the experiment as independent variables. To identify differences in the
same metrics between the experimental groups we performed one-way
analysis of variance (ANOVA) in females and males separately, using
exposure (DMSO, 20 and 70 µg/L) and week as independent variables.
Statistical analyses were performed in R.68
Behaviour measures
Each tank was videoed using an AXIS M1054 network camera (Axis
Communications, Luton, Bedfordshire, UK) with a video resolution of
1280 × 800 pixels, coupled to a Synology network-attached storage device
(NAS) (Synology Inc., Taipei, Taiwan). A laptop computer was used to
connect to the NAS, via the network, to view the tank in real time and to
record the tests and analyse behaviour. Each camera was clamped in front
of each tank and these were recorded for from 9.15 a.m. to 9.45 a.m.
(spawning), 11.00 a.m. to 11.30 a.m. (feeding) and 1.30 p.m. to 2.00 p.m.
(‘general time’) during the three days of the exposure. For analysis, we
paused the videos every minute, recorded the position of each fish
Fig. 5 Example of a module characterised by decreased connectivity between co-expressed genes following clozapine exposure. a There
is a highly significant decrease in connectivity within ‘Module 5’ following clozapine exposure, with the most dramatic decrease seen
following exposure to a ‘high’ dose of clozapine. b Connectivity for individual genes in ‘Module 5’ is lower following clozapine exposure
relative to connectivity in the DMSO control group. c Visual representation of connectivity between individual genes in ‘Module 5’ following
clozapine exposure (50 genes with higher connectivity), highlighting the clear dose-response relationship.
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(bottom, middle and top) and calculated the sum of the number of times
each fish spent in each position over the 30min. Analyses were performed
separately for each position in the tank (bottom, middle and top) at each
recording time (feeding, spawning and general time) and the three days of
each experiment were treated as independent observations. To identify
differences between the two control groups we performed a linear
regression using exposure (water and DMSO), sex and time (week) of the
experiment as independent variables. To identify clozapine exposure-
associated differences we performed one-way ANOVA using exposure
(DMSO, 20 and 70 µg/L), sex and time (week) of the experiment as
independent variables. Statistical analyses were performed in R.68
RNA sequencing
Total RNA was isolated from the whole brain samples using the AllPrep
DNA/RNA Micro Kit (Qiagen, Venlo, Holland) incorporating on-column
DNase treatment, according to the manufacturer’s instructions. RNA
samples were assessed for quality and purity using spectrophotometry
and an Agilent 2100 Bioanalyzer Instrument (Agilent Technologies, Santa
Clara, CA, USA) in conjunction with the Agilent RNA 6000 Nano Kit (Agilent
Technologies, Santa Clara, CA, USA) according to the manufacturer’s
instructions. The RNA integrity numbers (RIN) ranged from 8.30 to 10.00
(Supplementary Table 1).
ERCC spike-in control mixes (Ambion, Thermo Fisher Scientific, Waltham,
MA, USA) were added to all individual RNA samples, according to the
manufacturer’s instructions. cDNA libraries from all samples were then
prepared using the TruSeq Stranded mRNA Library Prep kit (Illumina, San
Diego, CA, USA), multiplexed with eight samples per lane and RNA-
sequencing was carried out on an Illumina HiSeq 2500 Sequencing System
(Illumina, San Diego, CA, USA) to generate 100 bp paired reads.
RNA-seq data pre-processing
Data pre-processing was performed in UNIX. The expression profiles of the
ERCC sequences were analysed against the manufacturer’s expression
values to check for accuracy of the transcript quantification and dynamic
range. Trimmomatic (v0.38)69 was used to quality trim the raw reads. The
raw and trimmed read were inspected using FastQC (v0.10.1).70 All samples
survived quality control (QC) and pre-processing and were used for further
analyses. RSEM71 (v1.3.1, using bowtie2 v 2.3.4.172) was used to align the
pre-processed reads to the zebrafish complementary reference transcrip-
tome (GRCz11 GCA_000002035.4) release 92, downloaded from Ensembl:
ftp://ftp.ensembl.org/pub/release-92/fasta/danio_rerio/cdna/). The number
of raw and trimmed reads, as well as the mapping efficiency for all samples
is shown in Supplementary Table 4. The ‘abundance_estimates_to_matrix.
pl’ script in RSEM71 was used to generate a matrix of estimated counts for
all samples (30,627 genes).
Differential expression analyses
Differential expression analyses were performed in R68 using the DMSO
and clozapine (20 and 70 µl/L) samples. Genes were considered as being
expressed when at least 10 reads in at least 16 samples (the exposure
group size) were obtained and 20,837 genes were taken further for
analysis. The ‘DESeq’ function from the R package DESeq2 (v1.14.1)73 was
used to perform the differential expression analyses. In total, 72 genes
were identified as having outliers based on their Cook’s distance. The
‘DESeq’ function replaces these values with the trimmed mean over all
samples (for details see Love et al.73). To identify clozapine exposure-
associated gene expression changes we performed a likelihood ration test
using exposure (DMSO, 20 and 70 µg/L), sex and week as independent
variables. To see if clozapine dose interacts with sex, we repeated the
analysis adding the interaction term ‘exposure*sex’. To identify changes
between the two control groups (water and DMSO), the expression values
of these two groups for the same 20,837 genes were extracted. We then
performed a Wald test (‘DESeq’ function, DESeq273) using exposure (water
and DMSO), sex and week as independent variables.
Co-expression network analysis
Network analysis on the gene expression values of the 20,837 genes that
survived QC was performed using the R package WGCNA (v1.66).74 We
created a signed network using the ‘blockwiseModules’ function (Pearson
correlation, soft thresholding power= 12, minimum module size= 20,
maximum block size= 5,000). The base 2 logarithms (log2) of the
normalised counts+ 1 of the DMSO, 20 µg/L and 70 µg/L groups were
used. ‘Module 0’ containing non-allocated genes was excluded from
further analysis. Connectivity values for each gene were calculated
separately for the DMSO, 20 and 70 µg/L groups using the ‘intramodu-
larConnectivity’ function on the absolute correlations between genes
raised to the power of 12. We performed a one-way ANOVA using the
‘within module connectivity’ (kWithin) of the three exposure groups of
interest (DMSO, 20 and 70 µg/L) to identify significant changes in module
connectivity with clozapine exposure.
Gene ontology pathway analysis
We tested for enrichment of GO75,76 terms in each of the modules
showing connectivity changes with clozapine. The R annotation package
org.Dr.eg.db (v 3.7.0)77 was used to extract updated GO terms for GRCz11
and terms with less than 10 genes were excluded from analyses. In total,
2,141 GO terms were assigned to genes in the dataset. The
‘makeTxDbFromBiomart’ function from the R package GenomicFeatures
(v1.34.1)78 was used to extract the length of the genes in the analyses.
For the genes allocated to each module, the ‘nullp’ and ‘goseq’ functions
from the R package goseq (v1.34.0)79 were used to calculate the
probability weighting function and test for GO term enrichment,
respectively. For the results of each module, we displayed the results
graphically using Cytoscape (v3.7.1).80
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Raw, trimmed and pre-processed RNA-seq data as well as the original behavioural
videos are available from https://osf.io/a97j8/ (https://doi.org/10.17605/OSF.IO/A97J8).
Differential gene expression results for all expressed transcripts is provided in the
Supplementary Data file.
CODE AVAILABILITY
The code used to produce the analyses in this manuscript, as well as the phenotype
file, can be found in https://git.exeter.ac.uk/jffpviana/ClozapineZebrafish.git.
Received: 21 August 2019; Accepted: 12 December 2019;
REFERENCES
1. World Health Organization. The World Health Report 2013: Research for Universal
Health Coverage. (World Health Organization, 2013).
2. World Health Organization. Schizophrenia Fact sheet N°397 (2015).
3. Burmeister, M., McInnis, M. G. & Zollner, S. Psychiatric genetics: progress amid
controversy. Nat. Rev. Genet 9, 527–540 (2008).
4. Hert, M., Schreurs, V., Vancampfort, D. & Winkel, R. Metabolic syndrome in people
with schizophrenia: a review. World Psychiatry 8, 15–22 (2009).
5. Porcelli, S., Balzarro, B. & Serretti, A. Clozapine resistance: augmentation strate-
gies. Eur. Neuropsychopharmacol. 22, 165–182 (2012).
6. Essali, A., Al-Haj Haasan, N., Li, C. & Rathbone, J. Clozapine versus typical neu-
roleptic medication for schizophrenia. Cochrane Database Syst Rev, CD000059,
https://doi.org/10.1002/14651858.CD000059.pub2 (2009).
7. Siskind, D., McCartney, L., Goldschlager, R. & Kisely, S. Clozapine v. first- and
second-generation antipsychotics in treatment-refractory schizophrenia: sys-
tematic review and meta-analysis. Br. J. Psychiatry 209, 385–392 (2016).
8. Bosia, M., Pigoni, A. & Cavallaro, R. Genomics and epigenomics in novel schizo-
phrenia drug discovery: translating animal models to clinical research and back.
Expert Opin. Drug Disco. 10, 125–139 (2015).
9. Rajagopal, S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Post-
grad. Med J. 81, 545–546 (2005).
10. Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schi-
zophrenia: a critical review of pharmacology and mechanisms of action of anti-
psychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
11. Duncan, C. E., Chetcuti, A. F. & Schofield, P. R. Coregulation of genes in the mouse
brain following treatment with clozapine, haloperidol, or olanzapine implicates
altered potassium channel subunit expression in the mechanism of antipsychotic
drug action. Psychiatr. Genet 18, 226–239 (2008).
J. Viana et al.
9
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2020)     3 
12. Thomas, E. A. et al. Antipsychotic drug treatment alters expression of mRNAs
encoding lipid metabolism-related proteins. Mol. Psychiatry 8, 983–993 (2003). 950.
13. Fatemi, S. H., Folsom, T. D., Reutiman, T. J., Novak, J. & Engel, R. H. Comparative
gene expression study of the chronic exposure to clozapine and haloperidol in
rat frontal cortex. Schizophr. Res. 134, 211–218 (2012).
14. Rizig, M. A. et al. A gene expression and systems pathway analysis of the effects
of clozapine compared to haloperidol in the mouse brain implicates susceptibility
genes for schizophrenia. J. Psychopharmacol. 26, 1218–1230 (2012).
15. Stewart, A. M., Braubach, O., Spitsbergen, J., Gerlai, R. & Kalueff, A. V. Zebrafish
models for translational neuroscience research: from tank to bedside. Trends
Neurosci. 37, 264–278 (2014).
16. Howe, K. et al. The zebrafish reference genome sequence and its relationship to
the human genome. Nature 496, 498–503 (2013).
17. Stewart, A. M. et al. Molecular psychiatry of zebrafish. Mol. Psychiatry 20, 2–17
(2015).
18. Norton, W. H. Toward developmental models of psychiatric disorders in zebrafish.
Front Neural Circuits 7, 79 (2013).
19. Zhao, S. S. et al. Drug screening: zebrafish as a tool for studying epileptic-related
chemical compounds. Protein Cell 6, 853–857 (2015).
20. Gut, P. et al. Whole-organism screening for gluconeogenesis identifies activators
of fasting metabolism. Nat. Chem. Biol. 9, 97–104 (2013).
21. Feng, C. W. et al. Effects of 6-hydroxydopamine exposure on motor activity and
biochemical expression in zebrafish (Danio rerio) larvae. Zebrafish 11, 227–239
(2014).
22. Urs, N. M., Nicholls, P. J. & Caron, M. G. Integrated approaches to understanding
antipsychotic drug action at GPCRs. Curr. Opin. Cell Biol. 27, 56–62 (2014).
23. Catapano, L. A. & Manji, H. K. G protein-coupled receptors in major psychiatric
disorders. Biochim. Biophys. Acta 1768, 976–993 (2007).
24. Bruni, G. et al. Zebrafish behavioral profiling identifies multitarget antipsychotic-
like compounds. Nat. Chem. Biol. 12, 559–566 (2016).
25. Boehmler, W. et al. D4 Dopamine receptor genes of zebrafish and effects of the
antipsychotic clozapine on larval swimming behaviour. Genes Brain Behav. 6,
155–166 (2007).
26. Wang, G. et al. Abnormal behavior of zebrafish mutant in dopamine transporter is
rescued by clozapine. iScience 17, 325–333 (2019).
27. Turner, B. J., Rembach, A., Spark, R., Lopes, E. C. & Cheema, S. S. Opposing effects
of low and high-dose clozapine on survival of transgenic amyotrophic lateral
sclerosis mice. J. Neurosci. Res 74, 605–613 (2003).
28. Pettersson, T., Ohlsson, O. & Tryding, N. Increased CKMB (mass concentration) in
patients without traditional evidence of acute myocardial infarction. A risk indi-
cator of coronary death. Eur. Heart J. 13, 1387–1392 (1992).
29. Knoph, K. N. et al. Clozapine-induced cardiomyopathy and myocarditis mon-
itoring: A systematic review. Schizophr. Res 199, 17–30 (2018).
30. Scelsa, S. N. et al. Clozapine-induced myotoxicity in patients with chronic psy-
chotic disorders. Neurology 47, 1518–1523 (1996).
31. Marcus, E. L., Vass, A. & Zislin, J. Marked elevation of serum creatine kinase
associated with olanzapine therapy. Ann. Pharmacother. 33, 697–700 (1999).
32. Hemmer, W. & Wallimann, T. Functional aspects of creatine kinase in brain. Dev.
Neurosci. 15, 249–260 (1993).
33. Hemmer, W., Zanolla, E., Furter-Graves, E. M., Eppenberger, H. M. & Wallimann, T.
Creatine kinase isoenzymes in chicken cerebellum: specific localization of brain-
type creatine kinase in Bergmann glial cells and muscle-type creatine kinase in
Purkinje neurons. Eur. J. Neurosci. 6, 538–549 (1994).
34. Romeo, S. et al. Population-based resequencing of ANGPTL4 uncovers variations
that reduce triglycerides and increase HDL. Nat. Genet 39, 513–516 (2007).
35. Wang, P. S. et al. Clozapine use and risk of diabetes mellitus. J. Clin. Psycho-
pharmacol. 22, 236–243 (2002).
36. Leary, S. C. et al. The human cytochrome c oxidase assembly factors SCO1 and
SCO2 have regulatory roles in the maintenance of cellular copper homeostasis.
Cell Metab. 5, 9–20 (2007).
37. Sato, M., Ohtomo, K., Daimon, T., Sugiyama, T. & Iijima, K. Localization of copper
to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in
cerebellum. J. Histochem Cytochem 42, 1585–1591 (1994).
38. Scheiber, I. F., Mercer, J. F. & Dringen, R. Copper accumulation by cultured
astrocytes. Neurochem. Int. 56, 451–460 (2010).
39. Schoonover, K. E., Queern, S. L., Lapi, S. E. & Roberts, R. C. Impaired copper
transport in schizophrenia results in a copper-deficient brain state: a new side to
the dysbindin story. World J. Biol. Psychiatry, 1-37, https://doi.org/10.1080/
15622975.2018.1523562 (2018).
40. Vidovic, B. et al. Selenium, zinc, and copper plasma levels in patients with schi-
zophrenia: relationship with metabolic risk factors. Biol. Trace Elem. Res 156,
22–28 (2013).
41. Gregg, J. R., Herring, N. R., Naydenov, A. V., Hanlin, R. P. & Konradi, C. Down-
regulation of oligodendrocyte transcripts is associated with impaired prefrontal
cortex function in rats. Schizophr. Res 113, 277–287 (2009).
42. Pegg, A. E. Regulation of ornithine decarboxylase. J. Biol. Chem. 281,
14529–14532 (2006).
43. Pegg, A. E. Functions of polyamines in mammals. J. Biol. Chem. 291, 14904–14912
(2016).
44. Fiori, L. M. & Turecki, G. Implication of the polyamine system in mental disorders.
J. Psychiatry Neurosci. 33, 102–110 (2008).
45. Morris, S. M. Jr. Arginine metabolism revisited. J. Nutr. 146, 2579S–2586S (2016).
46. Freudenberg, F., Alttoa, A. & Reif, A. Neuronal nitric oxide synthase (NOS1) and its
adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders. Genes Brain
Behav. 14, 46–63 (2015).
47. Uzbay, T. et al. Increased plasma agmatine levels in patients with schizophrenia. J.
Psychiatr. Res 47, 1054–1060 (2013).
48. Yanik, M. et al. Is the arginine-nitric oxide pathway involved in the pathogenesis
of schizophrenia? Neuropsychobiology 47, 61–65 (2003).
49. Liu, P. et al. Altered brain arginine metabolism in schizophrenia. Transl. Psychiatry
6, e871 (2016).
50. Gilad, G. M., Gilad, V. H., Casanova, M. F. & Casero, R. A. Jr. Polyamines and their
metabolizing enzymes in human frontal cortex and hippocampus: preliminary
measurements in affective disorders. Biol. Psychiatry 38, 227–234 (1995).
51. Bernstein, H. G. et al. Morphometric studies of the entorhinal cortex in neu-
ropsychiatric patients and controls: clusters of heterotopically displaced lamina II
neurons are not indicative of schizophrenia. Schizophr. Res. 33, 125–132 (1998).
52. He, Y. et al. Schizophrenia shows a unique metabolomics signature in plasma.
Transl. Psychiatry 2, e149 (2012).
53. Nabhan, J. F., Pan, H. & Lu, Q. Arrestin domain-containing protein 3 recruits the
NEDD4 E3 ligase to mediate ubiquitination of the beta2-adrenergic receptor.
EMBO Rep. 11, 605–611 (2010).
54. Patwari, P. et al. The arrestin domain-containing 3 protein regulates body mass
and energy expenditure. Cell Metab. 14, 671–683 (2011).
55. Han, S. O., Kommaddi, R. P. & Shenoy, S. K. Distinct roles for beta-arrestin2 and
arrestin-domain-containing proteins in beta2 adrenergic receptor trafficking.
EMBO Rep. 14, 164–171 (2013).
56. Gurevich, V. V. & Gurevich, E. V. The structural basis of arrestin-mediated reg-
ulation of G-protein-coupled receptors. Pharm. Ther. 110, 465–502 (2006).
57. Corley, S. M., Tsai, S. Y., Wilkins, M. R. & Shannon Weickert, C. Transcriptomic
analysis shows decreased cortical expression of NR4A1, NR4A2 and RXRB in
schizophrenia and provides evidence for nuclear receptor dysregulation. PLoS
ONE 11, e0166944 (2016).
58. Ahmed, M. R., Gurevich, V. V., Dalby, K. N., Benovic, J. L. & Gurevich, E. V. Halo-
peridol and clozapine differentially affect the expression of arrestins, receptor
kinases, and extracellular signal-regulated kinase activation. J. Pharm. Exp. Ther.
325, 276–283 (2008).
59. Rajasekaran, A., Venkatasubramanian, G., Berk, M. & Debnath, M. Mitochondrial
dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci.
Biobehav. Rev. 48, 10–21 (2015).
60. Roberts, R. C. Postmortem studies on mitochondria in schizophrenia. Schizophr.
Res. 187, 17–25 (2017).
61. Scaini, G. et al. Second generation antipsychotic-induced mitochondrial altera-
tions: Implications for increased risk of metabolic syndrome in patients with
schizophrenia. Eur. Neuropsychopharmacol. 28, 369–380 (2018).
62. Contreras-Shannon, V. et al. Clozapine-induced mitochondria alterations and
inflammation in brain and insulin-responsive cells. PLoS One 8, e59012 (2013).
63. Del Campo, A. et al. Metabolic Syndrome and Antipsychotics: The Role of
Mitochondrial Fission/Fusion Imbalance. Front Endocrinol. (Lausanne) 9, 144
(2018).
64. Mukai, J. et al. Molecular substrates of altered axonal growth and brain con-
nectivity in a mouse model of schizophrenia. Neuron 86, 680–695 (2015).
65. Johansson, A. S., Owe-Larsson, B., Hetta, J. & Lundkvist, G. B. Altered circadian
clock gene expression in patients with schizophrenia. Schizophr. Res. 174, 17–23
(2016).
66. Vaz, R., Hofmeister, W. & Lindstrand, A. Zebrafish models of neurodevelopmental
disorders: limitations and benefits of current tools and techniques. Int. J. Mol. Sci.
20, pii: E1296. https://doi.org/10.3390/ijms20061296 (2019).
67. Paull, G. C. et al. Variability in measures of reproductive success in laboratory-kept
colonies of zebrafish and implications for studies addressing population-level
effects of environmental chemicals. Aquat. Toxicol. 87, 115–126 (2008).
68. R: A language and environment for statistical computing. (R Foundation for
Statistical Computing, Vienna, 2015).
69. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina
sequence data. Bioinformatics 30, 2114–2120 (2014).
70. Andrews, S. FastQC: A quality control tool for high throughput sequence data.
http://www.bioinformatics.babraham.ac.uk/projects/fastqc (2010).
71. Hu, S., Wu, Z., Yan, Y. & Li, Y. Sox31 is involved in central nervous system ante-
roposterior regionalization through regulating the organizer activity in zebrafish.
Acta Biochim Biophys. Sin. (Shanghai) 43, 387–399 (2011).
J. Viana et al.
10
npj Schizophrenia (2020)     3 Published in partnership with the Schizophrenia International Research Society
72. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient
alignment of short DNA sequences to the human genome. Genome Biol. 10, R25
(2009).
73. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
74. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation
network analysis. BMC Bioinforma. 9, 559 (2008).
75. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene
Ontology Consortium. Nat. Genet 25, 25–29 (2000).
76. Gene Ontology, C. Gene Ontology Consortium: going forward. Nucleic Acids Res
43, D1049–D1056 (2015).
77. Carlson, M. org.Dr.eg.db: Genome wide annotation for Zebrafish. R package
version 3.3.0 (2016).
78. Lawrence, M. et al. Software for computing and annotating genomic ranges. PLoS
Comput Biol. 9, e1003118 (2013).
79. Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis
for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
80. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
ACKNOWLEDGEMENTS
This work was supported by a Medical Research Council (MRC) Project Grant (MR/
K013807/1) and Clinical Infrastructure Funding (MR/M008924/1) to JM. JV is funded
by an RCUK/UKRI Rutherford Fund Fellowship (MR/R024987/1). We would like to
acknowledge the use of the University of Exeter High-Performance Computing (HPC)
facility in carrying out this work.
AUTHOR CONTRIBUTIONS
J.V., E.S. and J.M. conceived the study and obtained funding. J.V. performed fish
experimental work, supervised by E.S. and G.P. J.V. undertook RNA-seq experiments
in conjunction with A.F., P.O’.N. and K.M. J.V. led all bioinformatic analyses. N.W.
performed behavioural scoring and analyses. E.H. and R.v.A. provided bioinformatic
support. J.V. and J.M. drafted the paper. The final paper was read and approved by all
authors.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41537-019-0092-x.
Correspondence and requests for materials should be addressed to J.M.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
J. Viana et al.
11
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2020)     3 
